Table 5.

Adherence to study drug.

	Placebo (n = 65)	MAG-EPA (n = 63)
Adherence to study drug for the entire study (%) *	91.9	93.3
Adherence to study drug until withdrawal or end of the study **	91.4	92.9
Adherence to study drug for all patients who underwent RP §	86.3	83.4
Adherence for patients who underwent RP and took at least 80% of study drug †	93.4	94.8

Notes: * Adherence to the study drug was calculated for the entire study for patients who completed the 12 Months Post-RP visit and had available compliance data for the entire study (n = 55 in placebo; n = 58 in MAG-EPA). ** Adherence to the study drug was calculated for all patients who had available data for compliance to the study drug before their withdrawal or the end of the study, whichever came first (n = 57 in placebo; n = 62 in MAG-EPA). § Adherence to study drug was calculated for all patients who underwent radical prostatectomy and had available data for compliance to study drug (n = 63 in placebo; n = 62 in MAG-EPA). For patients who withdrew from the study, subsequent visits compliance was considered to be 0%. † Adherence to the study drug was calculated for all patients who underwent radical prostatectomy and took at least 80% of the dose during the entire study (mean of all visits) (n = 54 in placebo; n = 52 in MAG-EPA). MAG-EPA: monoacylglyceride-conjugated eicosapentaenoic acid; RP: Radical prostatectomy.